One80 Intermediaries Launches GeneBridge Gene Therapy Reinsurance Product
The solution mitigates the financial impact of high-cost gene therapy claims.
GeneBridge is a reinsurance facility designed for blocks of business including employer stop loss programs and health plans. Programs that purchase GeneBridge are reimbursed up to a scheduled amount for the list price and administration of the FDA-approved therapies.
More than 10,000 diseases are linked to genetic disorders fueling a rapid growth in approved treatments. At an average cost per therapy of over
“With the number of gene and cell therapies expected to double over the next two years, we saw a great need to mitigate the potentially catastrophic financial impact one or more of these claims would have on programs and employer groups,” said
The program will be administered through One80’s medical stop loss practice, a full-service Managing General Underwriter.
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20240701143486/en/
Media Contact:
[email protected]
(786) 865-4614
Source:
What is long-term care insurance, and why are premiums still rising?
This Week: Job openings, Fed meeting minutes, June nonfarm payrolls report
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News